Thieler Law Corp advises investors with losses exceeding $100,000 of the January 19, 2016 lead plaintiff deadline in a class action lawsuit filed against Clovis Oncology Inc (NASDAQ: CLVS) (“Clovis” or “the Company”). The suit is pending in the U.S. District Court for the District of Colorado and investors, who purchased Clovis Oncology Inc securities between May 20, 2014 and November 13, 2015, have until January 19, 2016 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Clovis Oncology Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com .  No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose  that the New Drug Application (“NDA”) that Clovis submitted to the FDA for rociletinib contained immature data sets based on both unconfirmed response rates and confirmed response rates; that Clovis’ Breakthrough Therapy designation submission contained immature data set based primarily on unconfirmed responses; that Clovis presented interim data publicly and at medical meetings that included a data set based primarily on unconfirmed responses; that as the efficacy data matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected; that, as a result of the foregoing, Clovis’ NDA was likely to be delayed and/or rejected by the FDA; and that, as a result of the foregoing, the Defendants’ statements about Clovis’ business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

On November 16, 2015, Clovis Oncology Inc announced that potential approval of rociletinib, a lung cancer treatment, will probably be delayed due to FDA requesting more data with regard to the use of two different dosages and their response rates.

On this news, Clovis Oncology Inc shares fell $69.19 or over 69% to close at $30.24 on November 16, 2015.

If you were negatively impacted by your investment in Clovis Oncology Inc securities between May 20, 2014 and November 13, 2015, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185